Moret Berman RM, Darnell AM, Miller HL, et al. 1997. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry, 154:37–43. Bertschy G, Ragama-Pardos E, Ait-Ameur A, et al. 2003. Lithium augmentation in venlafaxine non-responders: an open study. Eur Psychiatry,18:314–17. Bijl D. 2004. The serotonin syndrome. Neth J Med, 62:309–13. Blier P, de Montigny C. 1994. Current advances and trends in the treatment of depression. Trends Pharmacol Sci, 15:220–6. Bodkin JA, Lasser RA, Wines JD Jr, et al. 1997. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry, 58:137–45. Bosker FJ, Westerink BH, Cremers TI, et al. 2004. Future antidepressants: what is in the pipeline and what is missing? CNS Drugs, 18:705–32. Celada P, Puig M, Amargos-Bosch M, et al. 2004. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci, 29:252–65. Chambless DL, Hollon SD. 1998. Defining empirically supported therapies. J Consult Clin Psychol, 66:7–18. Ciusani E, Zullino DF, Eap CB. et al. 2004. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J Psycho- pharmacol, 18:559–66. Clark NA, Alexander B. 2000. Increased rate of trazodone prescribing with bupropion and selective serotonin-reuptake inhibitors versus tricyclic antidepressants. Ann Pharmacother, 34:1007–12. Dietrich DE, Emrich HM. 1998. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry, 59 Suppl 5:51–8. Dimitriou EC, Dimitriou CE. 1998. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol, 18:465–9. Dong J, Blier P. 2001. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology, 155:52–7. Fava GA, Grandi S, Zielezny M, et al. 1994. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry, 151:1295–9. Fava GA, Rafanelli C, Grandi S, et al. 1998. Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. Arch Gen Psychiatry, 55:816–20. Fava GA, Savron G, Grandi S, et al. 1997. Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry, 58:278–82. Feinberg SS. 2004. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry, 65:1520–4. Ferrier IN. 1999. Treatment of major depression: is improvement enough? J Clin Psychiatry, 60(Suppl 6):10–14. Frank E, Prien RF, Jarrett RB, et al. 1991. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry, 48:851–5. Gagné GG Jr, Furman MJ, Carpenter LL, et al. 2000. Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am J Psychiatry, 157:1960–5. Gobbi G, Slater S, Boucher N, et al. 2003. Neurochemical and psychotropic effects of bupropion in healthy male subjects. J Clin Psychopharmacol, 23:233–9. Greenberg PE, Kessler RC, Birnbaum HG, et al. 2003. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry, 64:1465–75. Gur E, Lerer B, Newman ME. 1999. Chronic clomipramine and triiodothyronine increase serotonin levels in rat frontal cortex in vivo: relationship to serotonin autoreceptor activity. J Pharmacol Exp Ther, 288:81–7. Haddjeri N, Szabo ST, de Montigny C, et al. 2000. Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments. Neuropsychopharmacology, 22:346–56. Isaac MT. 2004. Review: combining pindolol with an SSRI improves early outcomes in people with depression. Evid Based Ment Health, 7:107. Jahn H, Schick M, Kiefer F, et al. 2004. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry, 61:1235–44. Joffe RT, Singer W, Levitt AJ, et al. 1993. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry, 50:387–93. Keller MB, McCullough JP, Klein DN, et al. 2000. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med, 342:1462–70. Kelsey JE. 2002. Treatment strategies in achieving remission in major depressive disorder. Acta Psychiatr Scand Suppl, 415:18–23. Kessler RC, Berglund P, Demler O, et al. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095–105. Kinney GG, Taber MT, Gribkoff VK. 2000. The augmentation hypothesis for improvement of antidepressant therapy: Is pindolol a suitable candidate for testing the ability of 5HT1A receptor antagonists to enhance SSRI efficacy and onset latency? Mol Neurobiol, 21: 137–52. Koch S, Perry KW, Bymaster FP. 2004. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology, 46:232–42. Lam RW, Hossie H, Solomons K, et al. 2004. Citalopram and bupropion- SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry, 65:337–40. Landen M, Bjorling G, Agren H, et al. 1998. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry, 59:664–8. Larisch R, Kley K, Nikolaus S, et al. 2004. Depression and anxiety in different thyroid function states. Horm Metab Res, 36:650–3. Lavori PW, Rush AJ, Wisniewski SR, et al. 2001. Strengthening clinical effectiveness trials: equipoise-stratified randomization. Biol Psychiatry, 50:792–801. Lavretsky H, Kim M-D, Kumar A, et al. 2003. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiatry, 64:1410–14. Lenox RH, Hahn CG. 2000. Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry, 61 Suppl 9:5–15. Leonard BE, McCartan D, White J, et al. 2004. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol, 19:151–80. Lieberman JA, Greenhouse J, Hamer RM, et al. 2005. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsycho- pharmacology, 30:445–60. Liu P, He FF, Bai WP, et al. 2004. Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine. Chin Med J, 117:189–94. Martinez D, Hwang D, Mawlawi O, et al. 2001. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology, 24:209–29. National Institute of Mental Health. 2003. Sequenced Treatment Alternatives to Relieve Depression (STAR*D) [online]. Accessed Jul 2005. URL: http://www.edc.gsph.pitt.edu/stard/public/index.html-ssi. 308 Neuropsychiatric Disease and Treatment 2005:1(4)